Preliminary report of extracorporeal blood purification therapy in patients receiving LVAD: Cytosorb or Jafron HA330.

Zhuldyz NurmykhametovaTimur LesbekovRymbay KaliyevBolat BekishevNilufar JabayevaSvetlana NovikovaLinar FaizovIvan VakhrushevYuriy Pya

Published in: The journal of extra-corporeal technology (2024)

Our preliminary results showed that hemoadsorption therapy using Cytosorb or Jafron hemoadsorption (HA) 330 may not be clinically beneficial for patients with advanced heart failure undergoing LVAD implantation. Large prospective studies are needed to evaluate the potential role of HA therapy in improving outcomes in patients undergoing LVAD implantation.

Keyphrases

heart failure
patients undergoing
left ventricular
risk assessment
metabolic syndrome
adipose tissue
mesenchymal stem cells
bone marrow
recombinant human